The ARUBA TrialARUBA is designed to determine whether symptom management with medicines improves long-term outcomes of patients with unruptured brain arteriovenous malformations (AVM’s) compared to interventional therapy, such as surgery, to remove the AVM. Patients are randomized to receive either medical management of any symptoms related to the AVM, or to receive an intervention. This study is open to patients over the age of 18 who have a known brain arteriovenous malformation, who have never undergone a procedure to treat the AVM, and who have never had any bleeding from the AVM. Patients must be willing to be followed in the study for a minimum of 5 years.

IRIS TrialIRIS tests a common medication, ACTOS®, for its effectiveness in preventing recurrent strokes in patients who have insulin resistance. A fasting blood test is needed to determine if a patient has this condition. The study is open to people over the age of 45, who have had a stroke in the past 6 months, are insulin resistant, and are not diabetic. Patients will be put into one of two groups. One group will receive placebo, and the other will receive medication. Patients must be willing to remain in the study for approximately 3 years.

IN-STRIDE logoINSTRIDE is a clinical trial comparing the effectiveness and safety of the WalkAide Neurostimulator device vs. a standard ankle foot orthosis (AFO) for patients who suffer foot drop due to stroke. The WalkAide is an external stimulator that allows patients with foot drop to walk with a normal gait pattern. Patients enrolled in the trial will receive either a WalkAide or an AFO. The patients will be followed for a period of a year to determine if the WalkAide will show improvement over the AFO. The trial is open to patients over the age of 18, who have foot drop due to a stroke, and are currently receiving Medicare or are eligible for Medicare. Patients must be willing to attend followup sessions at the Eastern Rehabilitation Network offices in East Hartford for one year. This study is sponsored by Innovative Neurotronics, Inc.

CLEAR-IICLEAR III is designed to compare 2 treatments for bleeding in the brain, to see which one has better results. Patients will be randomized to one of the 2 treatment groups. One group will have rt-PA (the “clot-busting” drug) administered directly into the brain by a small tube; the other group will have a placebo (a fluid that doesn’t contain any medicine) administered the same way. This study is open to patients age 18 to 80, who have been diagnosed with bleeding in 2 of the ventricles in the brain, and who meet other medical criteria. Patients in the study will be followed for 12 months. This study is sponsored by the National Institute of Neurological Disorders and Johns Hopkins University.

MISTIEMISTIE: The purpose of this trial is to determine the best method of removing a clot from the brain. Patients will either have surgery to remove the clot, or they will receive rt-PA (the “clot-buster” drug) administered directly into the clot through a small tube placed in the brain. This study is open to patients age 18 to 80, who have a diagnosis of sudden bleeding in the brain, and who meet other medical criteria. Patients in the study will be followed for 12 months. This study is sponsored by the National Institute of Neurological Disorders and Johns Hopkins University.
STICH II: This study is designed to compare treatments for bleeding in the brain. Patients will either have surgery very soon after the bleeding is diagnosed, or they will have surgery after a period of conservative treatment. This study is open to patients who are age 20 and over, and who have a diagnosis of bleeding in the brain, who meet other medical criteria, and who are being treated by a neurosurgeon whose opinion is that either treatment would benefit the patient. Patients in the study will be followed for 12 months. This study is sponsored by Newcastle General Hospital in the United Kingdom.
 

(top)